Tang Li, Duan Rui, Zhong Yan-jun, Firestone Raymond A, Hong Ya-ping, Li Ji-guo, Xin Yan-chao, Wu Han-lin, Li Yan
Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, No 169, Donghu Road, Wuhan 430071, China.
Mol Cancer. 2014 Mar 3;13:44. doi: 10.1186/1476-4598-13-44.
This work aimed to synthesize a cathepsin B (CTSB)-cleavable tumor-targeting prodrug peptide doxorubicin (PDOX) and study the in vivo efficacy and toxicities on an animal model of gastric peritoneal carcinomatosis (PC).
PDOX was synthesized using doxorubicin (DOX) attaching to a CTSB-cleavable dipeptide Ac-Phe-Lys and a para-amino-benzyloxycarbonyl (PABC) spacer. PC model was established by injecting VX2 tumor cells into the gastric sub-mucosa of 40 rabbits, which then were randomized into 4 groups: the Control (n = 10) without treatment, the HIPEC (n = 10) receiving cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC), the PDOX (n = 10) and the DOX (n = 10) receiving systemic chemotherapy with PDOX 50.0 mg/kg or DOX 5.0 mg/kg, respectively, after CRS + HIPEC.
The median overall survivals (OS) were 23.0 d (95% CI: 19.9 d - 26.1 d) in the Control, 41.0 d (36.9 d - 45.1 d) in the HIPEC, 65.0 d (44.1 d - 71.9 d) in the PDOX, and 58.0 d (39.6 d - 54.4 d) in the DOX. Compared with the Control, the OS was extended by 70% in the HIPEC (p < 0.001) and further extended by 40% in the DOX (p = 0.029) and by 58% in the PDOX (p = 0.021), and the PC severity was decreased in the HIPEC and further decreased in the PDOX and DOX. Animals receiving DOX treatment showed hematological toxicities with marked reduction of white blood cells and platelets, as well as cardiac toxicities with significant increases in creatine kinase mb isoenzyme, evident myocardium coagulation necrosis, significant nuclear degeneration, peri-nucleus mitochondria deletion, mitochondria-pyknosis, and abnormal intercalated discs. But these toxicities were not evident in the PDOX.
PDOX is a newly synthesized tumor-targeting prodrug of DOX. Compared with DOX, PDOX has similar efficacy but reduced hematological and cardiac toxicities in treating rabbit model of gastric PC.
本研究旨在合成一种组织蛋白酶B(CTSB)可裂解的肿瘤靶向前药肽阿霉素(PDOX),并研究其在胃腹膜癌(PC)动物模型中的体内疗效和毒性。
通过将阿霉素(DOX)连接到CTSB可裂解的二肽Ac-Phe-Lys和对氨基苄氧羰基(PABC)间隔基上来合成PDOX。将VX2肿瘤细胞注入40只兔子的胃黏膜下层建立PC模型,然后将其随机分为4组:对照组(n = 10)不进行治疗;热灌注化疗(HIPEC)组(n = 10)接受减瘤手术(CRS)加腹腔内热化疗(HIPEC);PDOX组(n = 10)和DOX组(n = 10)在CRS + HIPEC后分别接受50.0 mg/kg PDOX或5.0 mg/kg DOX的全身化疗。
对照组的中位总生存期(OS)为23.0天(95%CI:19.9天 - 26.1天),HIPEC组为41.0天(36.9天 - 45.1天),PDOX组为65.0天(44.1天 - 71.9天),DOX组为58.0天(39.6天 - 54.4天)。与对照组相比,HIPEC组的OS延长了70%(p < 0.001),DOX组进一步延长了40%(p = 0.029),PDOX组延长了58%(p = 0.021),且HIPEC组的PC严重程度降低,PDOX组和DOX组进一步降低。接受DOX治疗的动物出现血液学毒性,白细胞和血小板明显减少,以及心脏毒性,肌酸激酶同工酶mb显著升高,心肌明显凝固性坏死,细胞核显著变性,核周线粒体缺失,线粒体固缩,闰盘异常。但这些毒性在PDOX组中不明显。
PDOX是一种新合成的DOX肿瘤靶向前药。与DOX相比,PDOX在治疗兔胃PC模型中具有相似的疗效,但血液学和心脏毒性降低。